Skip Navigation

A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards and Recognition

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.


Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

Premier Inc. ProvideGx™ Program Partners with Pfizer Inc. to Provide Corvert® and Vincristine to Providers

CHARLOTTE, N.C. — Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Pfizer Inc. to supply Corvert® (ibutilide fumarate injection) and Vincristine Sulfate Injection, USP, to healthcare providers, to help stabilize the long-term supply of two vital medications for its members.

Corvert is an anti-arrhythmic heart medication used to treat atrial fibrillation or atrial flutter. Vincristine is a chemotherapy drug, primarily used to treat childhood cancers such as acute leukemia, and, in combination with other oncolytic agents, Hodgkin's and non- Hodgkin's lymphoma, rhabdomyosarcoma, neuroblastoma and Wilms’ tumor.

“Supporting a sustainable supply of these important medicines is a top priority for Premier and our members,” said Premier’s President, Michael J. Alkire. “This agreement speaks to the core strengths of the ProvideGx program - our ability to provide both short- and long-term solutions to support our members and patients. Together with our members, we have the nimbleness to act quickly when market events require it, thereby improving access and raising the bar for the entire drug supply chain. Moreover, the goal of ProvideGx is to create market stability and give manufacturers assurances to make the necessary investments for a consistent, long-term supply.”

Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list. Guided by health systems with more than 1,600 hospitals across the nation, Premier’s ProvideGx program has provided members access to more than 150 drugs that are or have been recently designated as shortage drugs, including metoprolol; cysteine hydrochloride; sodium bicarbonate; diphenhydramine; hydromorphone; lidocaine; morphine; thiamine; phytonadione injection; and emergency, pre-filled syringes of calcium chloride, epinephrine, sodium bicarbonate, atropine sulfate, dextrose and lidocaine. The program plans to introduce additional drugs from a target list of more than 50 products in months to come.

“Patients need continued access to these critical drugs and important treatments, “said Jerry Storm, Senior Vice President of Pharmacy Services at OSF HealthCare of Peoria, IL. “We commend Premier and Pfizer for reaching this deal to support long-term access to these medications now so that we can go back to the business of providing care to our patients that results in outstanding outcomes. Having a reliable supply of these drugs is critical for patients who can’t afford to wait, and crucial for their survival.”

ProvideGx is part of Premier’s ongoing effort to help facilitate the availability of high-quality products, including drugs for which there may be supply challenges. In doing so, Premier is working to insulate its members from supply fluctuations that may affect the market at large.

“Over the past several years, Pfizer has made significant advancements in addressing drug shortages, including investing $2 billion to modernize manufacturing and increase capacity,” said Suneet Varma, Global President, Pfizer Hospital. “This agreement with Premier continues to build on these efforts -- which we hope will ultimately increase patient access to two vital medicines, Corvert and Vincristine -- helping to drive market sustainably in the long term.”

The financial terms of Premier’s agreement with Pfizer were not disclosed.

Forward-Looking Statements

Matters discussed in this release that are not statements of historical or current facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC and available on Premier’s website at Forward-looking statements speak only as of the date they are made. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

Login Register Change Registration